Objective. To evaluate the efficacy and safety of CHDI in the treatment of
influenza infection. Method. A randomized double-blind, double dummy trial was conducted.
Influenza patients with a positive
influenza A rapid test diagnosis were randomized to receive CHDI or
oseltamivir. Primary outcome was assessed by the median
fever alleviation time and clearance time, and secondary outcome was total scores of
influenza symptoms. Results. One hundred thirty-nine participants were screened and 34 had a RT-PCR laboratory confirmation of influenza virus
infection.
Fever alleviation time was 2.5 and 5 hours in CHDI and
oseltamivir, respectively, and
fever clearance time was 32.5 and 49 hours. The HR of
fever alleviation and clearance time shows no significant difference between two groups. Total scores of
influenza symptoms descended significantly in both groups
after treatment and descended more in CHDI than
oseltamivir on day 2. Similar to total symptoms severity score,
fever severity score descend more significantly in CHDI than
oseltamivir on day 2, and there were no differences on other symptoms. Conclusions. CHDI have a similar effect to
oseltamivir in reducing the duration of
influenza illness. CHDI was well tolerated, with no serious adverse events noted during the study period.